Tag: CHMP
Biocon Biologics announces positive CHMP opinion for its biosimilar to treat...
The CHMP positive opinion will be considered by the European Commission whose decision on the approval is expected by the end of September 2023
Biocon & Mylan announce positive CHMP opinion for Ogivri, biosimilar Trastuzumab
The endorsement by European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) opens up opportunities towards tapping approximately $1.9 billion market for the product in Europe...………….